经皮肝穿刺射频热凝治疗原发性小肝癌  

Percutaneous radiofrequency ablation for small primary hepatic cancer

作　　者：朱彤[1] 沈英[1] 范峻 王莹[1] 

机构地区：[1]上海市第八人民医院外科,上海200233

出　　处：《中国普通外科杂志》2002年第9期522-524,共3页China Journal of General Surgery

摘　　要：目的　探讨经皮肝穿刺射频热凝 (PRFA)治疗肝癌的效果和适应证。方法　对 16例原发性小肝癌患者行PRFA治疗的临床资料进行回顾性分析。结果　 16例肝癌的直径均≤ 3cm。PRFA治疗后甲胎蛋白转阴者占 93 .3 % (14 / 15 )。B超 ,CT复查肿瘤缩小 ,并有包膜形成。 0 .5 ,1,2年生存率分别为 93 .8% ,10 0 % ,10 0 %。结论　PRFA是一种具有微创、时间短、安全方便、疗效可靠的治疗小肝癌的新方法。尤其适于有手术禁忌症 ,或有手术指征但位于肝中央区、临近腔静脉或肝门区的小肝癌。Objective To study the efficacy and indications of percutaneous radiofrequency ablation (PRFA) for small primary liver cancer(SPLC). Methods The clinical data of 16 patients with SPLC treated by PRFA were analysed retrospectively. Results The diameter of tumor in all 16 patients were ≤3cm. After PEFA, AFP from postive returned to negative in 93.3% of patients; and BUS and CT showed the tumors shrinking with capsule formation. The 0.5,1,2-year survival rate were 93.8%,100%,100% respectively. Conclusions PRFA for SPLC has advantages such as minitrauma, safe and effective, especiolly suitable to the patients with contrainsications of operation, or the tumor locating to the deep position of liver, or around inferior vena cava, hepatic veins or hepatic porta etc.

关 键 词：原发性小肝癌 肝肿瘤 射频热凝 经皮肝穿刺 并发症 

分 类 号：R735.705[医药卫生—肿瘤]